News IceCure Medical Ltd

Equities

ICCM

IL0011224156

Delayed Nasdaq Other stock markets 02:45:41 2024-05-21 pm EDT			5-day change	1st Jan Change
1.09 ^USD	+3.81%		-2.67%	+1.88%

May. 07	Icecure Medical Ltd. Announces That Positive Data from an Independent Study (The "Study") Performed in Japan Was Published in an Article Titled "Percutaneous Ultrasound?Guided Cryoablation for Early?Stage Primary Breast Cancer: A Follow?Up Study in Japan," in the Journal Breast Cancer on April 27, 2024	CI
Apr. 15	IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024	08:53am	PR
IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase	May. 20	PR
Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally	May. 07	PR
Icecure Medical Ltd. Announces That Positive Data from an Independent Study (The "Study") Performed in Japan Was Published in an Article Titled "Percutaneous Ultrasound?Guided Cryoablation for Early?Stage Primary Breast Cancer: A Follow?Up Study in Japan," in the Journal Breast Cancer on April 27, 2024	May. 07	CI
IceCure Medical : Company Presentation	Apr. 23	PU
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate, Data Submitted to FDA Requesting Marketing Authorization	Apr. 16	AQ
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer	Apr. 15	MT
IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense	Apr. 15	CI
IceCure Submits FDA Regulatory Filing for New XSense Cryoablation System with Cryoprobes	Apr. 03	AQ
Transcript : IceCure Medical Ltd, 2023 Earnings Call, Apr 03, 2024	Apr. 03
IceCure Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 03	CI
IceCure Medical Seeks FDA Clearance for Cryoablation Technology	Apr. 02	MT
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes	Apr. 02	PR
Icecure Submits FDA Regulatory Filing for New Xsense? Cryoablation System with Cryoprobes	Apr. 02	CI
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024	Mar. 27	PR
Alliance Global Partners Adjusts IceCure Medical Price Target to $2.90 From $1.90, Maintains Buy Rating	Mar. 20	MT
IceCure Medical Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study	Mar. 20	AQ
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy	Mar. 19	PR
IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study	Mar. 19	CI
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes	Mar. 12	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News IceCure Medical Ltd

Equities

ICCM

IL0011224156

Summary

Filters